Navigation Links
PuraMed BioScience®, Inc. Reports Increased Revenue From Sales of LipiGesic® M, Its Flagship Migraine Pain Relief Product
Date:2/15/2012

SCHOFIELD, Wis., Feb.15, 2012 /PRNewswire/ -- PuraMed BioScience®, Inc. (OTC Bulletin Board: PMBS), the producer of over-the-counter medicinal and healthcare products, announced today its financial results for the second quarter ended December 31, 2011 in conjunction with the publication of its quarterly 10Q SEC filing.

PuraMed BioScience reported net revenues for the three months ended December 31, 2011 of $608,676 compared to $1,869 for the same three month period ended December 31, 2010. The increase in revenue was primarily generated from initial orders of their unique, non-prescription migraine product, LipiGesic® M, by Walgreens, the #1 drug-store chain in the country.

For this same period, PuraMed BioScience also reported gross profits of $490,581 compared to $1,116 for the same three month period ended December 31, 2010. As a result of the rapid expansion into 15,000 stores and the associated increased advertising costs, the Company had a negative working capital (current assets minus current liabilities), as of December 31, 2011.  The Company is actively seeking additional capital to accomplish its planned business strategy and support its projected expenses.

"The revenue received from the successful roll-out of our product at national retail drug stores will play a key role in fulfilling our capital needs," said Sue Baacke, CFO of PuraMed BioScience. "The earnings demonstrated during the last quarter of 2011, indicate the Company's ability to satisfy operating expenses associated with the roll-out of LipiGesic M. As liabilities are addressed, we will continue to build equity for our shareholders as we expand the market presence of LipiGesic M."

According to PuraMed BioScience CEO Russell Mitchell, "This quarter represents an important milestone for PuraMed as it is the first quarter which we were able to successfully show income from operations.  It should be noted that this quarter only reflects initial revenue from Walgreens and we anticipate experiencing continued growth of revenue with the addition of CVS and additional retail opportunities worldwide."

LipiGesic M is a clinically tested homeopathic medication that has been shown to be highly effective and safe as a treatment formigraines. This sublingual formulation is now available as an over-the-counter product in major retail drug stores nationwide.

Mitchell added, "LipiGesic M's presence on retail shelves will also help fill the void left by recent OTC migraine medication recalls.   We remain confident that continued execution of our business strategy to generate an increase of sales will result in increased value for our shareholders."

About the Company:

PuraMed BioScience, Inc. engages in the research, development and marketing of non-prescription medicinal and healthcare products. In addition to its clinically tested, leading product LipiGesic® M, which provides first-line therapy for relief of acute migraine headache pain; the Company also has plans to launch LipiGesic® PM as a remedy for insomnia and other sleep disorders as well as LipiGesic® H for common tension headaches. For more information on PuraMed BioScience, Inc., visit the Company website at www.PuraMedBioScience.com, join the Company's group page on Facebook by searching "PuraMed BioScience" and follow the Company on Twitter at www.twitter.com/lipigesic.

Forward Looking Statements:

This news release contains forward-looking statements regarding PuraMed BioScience and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different than those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.

For more information, contact:

Russell Mitchell, Chairman and CEO
PuraMed BioScience, Inc.
715-359-6373
rmitchell@PuramedBioScience.com
Website: www.PuramedBioScience.com

Investor Relations:
Investor Awareness, Inc.
Tony Schor or James Foy, 847-945-2222
Website: www.investorawareness.com


'/>"/>
SOURCE PuraMed BioScience, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PuraMed BioScience, Inc. Announces LipiGesic®M, Their Unique Migraine Treatment, is Now Available for Purchase at CVS, the 2nd Largest Drug Chain in the United States
2. PuraMed BioScience, Inc. Has Its Lead Product, LipiGesic®M Featured in Flaherty Financial News
3. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be Held on February 15, 2012
4. Masimo Reports Fourth Quarter and Full Year 2011 Financial Results; Provides 2012 Financial Guidance
5. Cynosure Reports 53% Increase in Revenues and Returns to Profitability in the Fourth Quarter of 2011
6. Vanda Pharmaceuticals Reports Fourth Quarter 2011 and Full Year 2011 Results
7. Winner Medical Reports First Quarter of Fiscal 2012 Results
8. ThermoGenesis Reports Second Quarter Fiscal 2012 Results
9. Ampio Pharmaceuticals Reports Full-Year 2011 Financial Results and Milestone Highlights for 2011
10. Biosensors Reports Continued Strong Sales and Earnings Growth in the Third Quarter of Fiscal Year 2012
11. Misonix Reports a 29% and 24% Increase in Revenue for the Second Quarter and Six Months Fiscal 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... --  ZappRx, Inc ., a digital health company focused on ... it closed $25 million in Series B funding led by ... Seattle that is part of a ... B round included participation from SR One , who ... (formerly Google Ventures). As part of the financing, ...
(Date:4/20/2017)... , April 20, 2017 Eyevensys, ... the first non-viral gene expression technology that enables the ... eye to address a wide range of ophthalmic diseases, ... and Healthcare products Regulatory Agency (MHRA) to advance its ... ...
(Date:4/19/2017)... - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces that ... Conference 2017 at the Sheraton Hotel in Toronto, Ontario ... of the Company is scheduled to present on Tuesday, May 2 ... the Chairman of the Board, Tony Holler will also ... For more ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... 2017 , ... Accreditation Commission for Health Care (ACHC) is ... (HCAOA). This agreement allows HCAOA members to receive special pricing on ACHC’s Home ... University (AU) educational resources that help prepare HCAOA members for ACHC Accreditation. , ...
(Date:4/28/2017)... Clara, CA (PRWEB) , ... April 28, 2017 ... ... is pleased to announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep ... user experience, since it streamlines the reporting process and provides a familiar interface ...
(Date:4/28/2017)... ... ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced today that ... as “stable.” At the same time, the ratings agency cautioned that the company’s rating ... “capital adequacy” thresholds required for its strong rating. , “Horizon is committed to being ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, ... the GlycoMark test throughout the Northeast U.S. , GlycoMark is the only ... The GlycoMark test provides a clinically proven one- to two-week measure of hyperglycemic ...
(Date:4/28/2017)... ... 2017 , ... Ushio America proudly introduces the new ... solution for F32T8 fluorescent lamps on most instant-start and programmed-start electronic ballasts so ... lamps utilize the existing electronic ballast, saving labor and maintenance costs. It’s easy ...
Breaking Medicine News(10 mins):